Subsidiary Bankruptcy and Deconsolidation (Details) - USD ($)				12 Months Ended
	Oct. 31, 2020	Jul. 24, 2020	Apr. 26, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Oct. 02, 2019	Jul. 02, 2019	Feb. 08, 2019	Feb. 05, 2019
Business Acquisition, Contingent Consideration [Line Items]
Gain (loss) on deconsolidation of subsidiary				$ 0	$ 2,678,000	$ 0
Bankruptcy claims, amount paid to settle claims		$ 800,000
Gain from release of certain liabilities	$ 3,364,000			3,364,000	0	$ 0
Specialty Pharma
Business Acquisition, Contingent Consideration [Line Items]
Equity method investments, fair value										$ 0
Gain (loss) on deconsolidation of subsidiary					2,678,000
Speciality Pharama
Business Acquisition, Contingent Consideration [Line Items]
Aggregate cash proceeds of intangible assets and remaining inventory			$ 250,000
Serenity Pharmaceuticals, LLC
Business Acquisition, Contingent Consideration [Line Items]
Loss Contingency, Damages Sought, Value		3,096,000
Serenity Pharmaceuticals, LLC | Minimum
Business Acquisition, Contingent Consideration [Line Items]
Loss Contingency, Damages Sought, Value		$ 50,000,000
Internal Revenue Service (IRS) | Speciality Pharama
Business Acquisition, Contingent Consideration [Line Items]
Bankruptcy claims, amount of filed claims likely to be denied				1,937,000			$ 9,302,000	$ 50,695,000
Bankruptcy claims, amount paid to settle claims				1,937,000
DIP Credit Agreement | Debtor in Possession Credit and Security Facility
Business Acquisition, Contingent Consideration [Line Items]
Gain (loss) on deconsolidation of subsidiary					407,000
Payments for debtor in possession financing				$ 0	$ 407,000
DIP Credit Agreement | Debtor in Possession Credit and Security Facility | Speciality Pharama
Business Acquisition, Contingent Consideration [Line Items]
DIP financing, amount arranged									$ 2,700,000